Javaid_2021_Curr.Pharm.Des_27_3591

Reference

Title : Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential - Javaid_2021_Curr.Pharm.Des_27_3591
Author(s) : Javaid N , Shah MA , Rasul A , Chauhdary Z , Saleem U , Khan H , Ahmed N , Uddin MS , Mathew B , Behl T , Blundell R
Ref : Curr Pharm Des , 27 :3591 , 2021
Abstract :

Neurodegeneration is a multifactorial process involved the different cytotoxic pathways that lead to neuronal cell death. Alzheimer's disease (AD) is a persistent neurodegenerative disorder that normally has a steady onset and gradually worsens. Neuropathology, AD is characterized by the presence of neuroinflammation, mitochondrial dysfunction, increased oxidative stress, decreased antioxidant defense as well as increased acetylcholinesterase activity. Moreover, enhanced expression of amyloid precursor proteins leads to neural apoptosis, which has a vital role in the degeneration of neurons. The inability of commercial therapeutics to treat a single feature of AD pathology leads to the attraction towards organic drugs. Ellagic acid is a dimer of gallic acid; latest studies revealed that ellagic acid can initiate numerous cell signaling transmissions and decrease the progression of neurodegeneration. The neuroprotective effects of ellagic acid to protect the neurons against neurodegenerative events are due to its antioxidant effect, iron chelating, and mitochondrial protective effect. The main goal of this review is to critically analyze the molecular mechanism of action of ellagic acid against AD.

PubMedSearch : Javaid_2021_Curr.Pharm.Des_27_3591
PubMedID: 33183192

Related information

Citations formats

Javaid N, Shah MA, Rasul A, Chauhdary Z, Saleem U, Khan H, Ahmed N, Uddin MS, Mathew B, Behl T, Blundell R (2021)
Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Curr Pharm Des 27 :3591

Javaid N, Shah MA, Rasul A, Chauhdary Z, Saleem U, Khan H, Ahmed N, Uddin MS, Mathew B, Behl T, Blundell R (2021)
Curr Pharm Des 27 :3591